Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis

Atherosclerosis

Volumn 224, Issue 1, 2012, Pages 187-194

  Jiang, Jianping ^a   Chen, Pingyan ^a   Chen, Jianghua ^b   Yu, Xueqing ^c   Xie, Di ^a   Mei, Changlin ^d   Xiong, Fei ^e   Shi, Wei ^f   Zhou, Wei ^g   Liu, Xusheng ^h   Sun, Shiren ^k   Zhang, Ping ^b   Yang, Xiao ^c   Zhang, Yixiang ^d   Zhang, Yanmin ^e   Liang, Xinling ^f   Zhang, Zhimin ^g   Lin, Qizhan ^h   Yu, Yan ⁱ   Miyata, Toshio ^j   Tian, Jianwei ^a   Liang, Min ^a   Luo, Weihong ^a   Xu, Xin ^a   Hou, Fanfan ^a   more..

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^f GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^g 309TH HOSPITAL OF PLA   (China)

^h GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

ⁱ FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^j TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k NONE

more..

Author keywords

Advanced glycation end products; Cardiovascular morbidity; Glucose; Peritoneal dialysis; Skin autofluorescence

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE;

ADULT; ARTICLE; AUTOFLUORESCENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HEART FAILURE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC STRESS; MORBIDITY; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; STROKE;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHINA; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; OPTICAL IMAGING; PERITONEAL DIALYSIS; RENAL DIALYSIS; SKIN;

EID: 84865376010     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.06.022     Document Type: Article

References (39)

1. Levey A.S., Beto J.A., Coronado B.E., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National kidney foundation task force on cardiovascular disease. Am J Kidney Dis 1998, 32:853-906.
2. van Dijk P.C., Jager K.J., de Charro F., et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001, 16:1120-1129.
3. Miyata T., Wada Y., Cai Z., et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997, 51:1170-1181.
4. Mimura T., Takenaka T., Kanno Y., Aoki H., Ohshima J., Suzuki H. Comparison of changes in pulse wave velocity in patients on continuous ambulatory peritoneal dialysis and hemodialysis one year after introduction of dialysis therapy. Adv Perit Dial 2005, 21:139-145.
5. Hou F.F., Ren H., Owen W.F., et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004, 15:1889-1896.
6. Miyata T., Horie K., Ueda Y., et al. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000, 58:425-435.
7. Makita Z., Radoff S., Rayfield E.J., et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325:836-842.
8. Baynes JWThorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48:1-9.
9. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
10. Locatelli F., Canaud B., Eckardt K.U., Stenvinkel P., Wanner C., Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003, 18:1272-1280.
11. Galler A., Muller G., Schinzel R., Kratzsch J., Kiess W., Munch G. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. Diabetes Care 2003, 26:2609-2615.
12. Baynes J.W. From life to death-the struggle between chemistry and biology during aging: the Maillard reaction as an amplifier of genomic damage. Biogerontology 2000, 1:235-246.
13. Meerwaldt R., Hartog J.W., Graaff R., et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005, 16:3687-3693.
14. Tanaka K., Tani Y., Asai J., et al. Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients. Nephrol Dial Transplant 2011, 26:214-220.
15. Lutgers H.L., Gerrits E.G., Graaff R., et al. Skin autofluorescence provides additional information to the UK prospective diabetes study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009, 52:789-797.
16. Tanaka K., Katoh T., Asai J., et al. Relationship of skin autofluorescence to cardiovascular disease in Japanese hemodialysis patients. Ther Apher Dial 2010, 14:334-340.
17. Meerwaldt R., Lutgers H.L., Links T.P., et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007, 30:107-112.
18. Hricik D.E., Wu Y.C., Schulak A., Friedlander M.A. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Clin Transplant 1996, 10:568-573.
19. Meerwaldt R., Graaff R., Oomen P.H., et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004, 47:1324-1330.
20. den Hollander N.C., Mulder D.J., Graaff R., et al. Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia. J Inherit Metab Dis 2007, 30:916-923.
21. Hartog J.W., Hummel Y.M., Voors A.A., et al. Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail 2008, 14:596-602.
22. Krediet RTBalafa O. Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol 2010, 6:451-460.
23. McIntyre N.J., Chesterton L.J., John S.G., et al. Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol 2010, 5:51-55.
24. Goodkin D.A., Bragg-Gresham J.L., Koenig K.G., et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol 2003, 14:3270-3277.
25. Nieminen M.S., Bohm M., Cowie M.R., et al. Diagnosis and treatment of acute heart failure. Guidelines of the European society of cardiology. Kardiol Pol 2005, 63:143-186. discussion 187-89.
26. O'Hare A., Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol 2001, 12:2838-2847.
27. Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet; 379: 815-22.
28. Hartog J.W., de Vries A.P., Lutgers H.L., et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 2005, 1043:299-307.
29. Witowski J., Jorres A., Korybalska K., et al. Glucose degradation products in peritoneal dialysis fluids: do they harm?. Kidney Int Suppl 2003, S148-S151.
30. Pischetsrieder M. Chemistry of glucose and biochemical pathways of biological interest. Perit Dial Int 2000, 20(Suppl. 2):S26-S30.
31. Selby N.M., Fialova J., Burton J.O., McIntyre C.W. The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids. Nephrol Dial Transplant 2007, 22:870-879.
32. Williams J.D., Topley N., Craig K.J., et al. The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004, 66:408-418.
33. Nakayama M., Kawaguchi Y., Yamada K., et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997, 51:182-186.
34. Tomo T. Peritoneal dialysis solutions low in glucose degradation products-evidence for clinical benefits. Perit Dial Int 2008, 28(Suppl. 3):S123-S127.
35. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003, 21:3-12.
36. Smit AJ Gerrits E.G. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens 2010, 19:527-533.
37. Yan S.F., Ramasamy R., Naka Y., Schmidt A.M. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003, 93:1159-1169.
38. Guo Z.J., Niu H.X., Hou F.F., et al. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 2008, 10:1699-1712.
39. D'Agati V., Yan S.F., Ramasamy R., Schmidt A.M. RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends Endocrinol Metab 2010, 21:50-56.